

# Rasimcan Meral

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9108835/publications.pdf>

Version: 2024-02-01

17  
papers

428  
citations

1040056

9  
h-index

996975

15  
g-index

17  
all docs

17  
docs citations

17  
times ranked

736  
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhibition of IKK $\epsilon$ and TBK1 Improves Glucose Control in a Subset of Patients with Type 2 Diabetes. <i>Cell Metabolism</i> , 2017, 26, 157-170.e7.	16.2	127
2	Spectrum of disease associated with partial lipodystrophy: lessons from a trial cohort. <i>Clinical Endocrinology</i> , 2017, 86, 698-707.	2.4	72
3	Phenotypic and Genetic Characteristics of Lipodystrophy: Pathophysiology, Metabolic Abnormalities, and Comorbidities. <i>Current Diabetes Reports</i> , 2018, 18, 143.	4.2	53
4	Chronic ACE Inhibitor use is Associated with Decreased Odds of Severe Disease in Patients with COVID-19. <i>Anatolian Journal of Cardiology</i> , 2020, 24, 21-29.	0.9	36
5	Metabolic Parameters, Weight Loss, and Comorbidities 4 Years After Roux-en-Y Gastric Bypass and Sleeve Gastrectomy. <i>Obesity Surgery</i> , 2018, 28, 3415-3423.	2.1	31
6	Update on Therapeutic Options in Lipodystrophy. <i>Current Diabetes Reports</i> , 2018, 18, 139.	4.2	25
7	“Fat Shadows” From DXA for the Qualitative Assessment of Lipodystrophy: When a Picture Is Worth a Thousand Numbers. <i>Diabetes Care</i> , 2018, 41, 2255-2258.	8.6	18
8	Natural history of ROHHAD syndrome: development of severe insulin resistance and fatty liver disease over time. <i>Clinical Diabetes and Endocrinology</i> , 2019, 5, 9.	2.7	17
9	Metreleptin therapy for nonalcoholic steatohepatitis: Open-label therapy interventions in two different clinical settings. <i>Med</i> , 2021, 2, 814-835.e6.	4.4	12
10	Potential association of LMNA-associated generalized lipodystrophy with juvenile dermatomyositis. <i>Clinical Diabetes and Endocrinology</i> , 2018, 4, 6.	2.7	8
11	Cardiac phenotype in familial partial lipodystrophy. <i>Clinical Endocrinology</i> , 2021, 94, 1043-1053.	2.4	7
12	Diagnosis of acquired generalized lipodystrophy in a single patient with T-cell lymphoma and no exposure to Metreleptin. <i>Clinical Diabetes and Endocrinology</i> , 2019, 5, 4.	2.7	6
13	The Metabolic Equivalent BMI in Patients with Familial Partial Lipodystrophy (FPLD) Compared with Those with Severe Obesity. <i>Obesity</i> , 2021, 29, 274-278.	3.0	6
14	The complicated clinical course in a case of atypical lipodystrophy after development of neutralizing antibody to metreleptin: treatment with setmelanotide. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2020, 2020, .	0.5	5
15	Endogenous Leptin Concentrations Poorly Predict Metreleptin Response in Patients With Partial Lipodystrophy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e1739-e1751.	3.6	5
16	Effect of Socks on the Assessment of Vibration Sensation. <i>ISRN Neurology</i> , 2013, 2013, 1-5.	1.5	0
17	2287 ECG and echo characteristics in familial partial lipodystrophy: The impact of Lamin A variants. <i>Journal of Clinical and Translational Science</i> , 2018, 2, 41-42.	0.6	0